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Early Diagnosis of Alzheimer’s Disease in the Primary Care Setting
Abstract
The burden of Alzheimer’s disease (AD) affects not just the individual but also families, providers, and
society. Early recognition and diagnosis of AD may reduce cost by reducing interaction with the health
care system, earlier initiation of treatment, and prolonging time to long- term care. Primary care providers,
the first contact for diagnosis of patients with AD, are not fulfilling the potential of early diagnosis for a
variety of reasons. Biomarkers of AD emerge on average 15 to 20 years before clinical diagnosis, yet
currently established biomarkers are not easily available in the primary care setting. A growing body of
literature is focused on identifying additional non-invasive early signs of AD. The aims of this program of
research were to understand factors contributing to the AD diagnosis variability in primary care settings
and methods to improve early diagnosis by primary care providers. Four studies were undertaken to
achieve these aims. The first study reported the results of an integrated review estimating the prevalence
of missed diagnosis in primary care when compared to trained raters’ diagnoses. The findings call to
attention the difficulty primary care providers face to detect and diagnose AD at all levels of the
healthcare system. This led to the second study. Chronic pain is a common comorbid ailment seen in
those with AD and often is a driving factor of patients seeking medical care. In order to understand the
pain experience in those with worsening cognition, the second study was a secondary analysis of a crosssectional age- and sex-matched two group cohort study and found that the experience of pain differs
between males and females as a measure of cognition worsened suggesting a possible role of pain as a
tool to distinguish those at risk for AD. This finding led to the third study, which was a narrative review
conducted to describe how alterations in senses have been associated with the diagnosis of AD. The
results suggested differences in smell, taste, vision, hearing, and proprioception were associated with
different levels of the AD continuum but points out an obvious gap in the literature concerning other
senses. This led to the fourth study examining evidence that the ε4 allele of Apolipoprotein E modifies the
experience of pain in those individuals carrying the allele such that greater temperatures are required to
elicit pain and the experience of that pain is more unpleasant. Additional studies should expand on the
results of this pilot study.
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Abstract

Raymond R. Romano
Early Diagnosis of Alzheimer’s Disease in the
Primary Care Setting
The burden of Alzheimer’s disease (AD) affects not just the individual but also families, providers, and society. Early recognition and diagnosis of AD may reduce cost by
reducing interaction with the health care system, earlier initiation of treatment, and prolonging time to long- term care. Primary care providers, the first contact for diagnosis of
patients with AD, are not fulfilling the potential of early diagnosis for a variety of reasons.
Biomarkers of AD emerge on average 15 to 20 years before clinical diagnosis, yet currently
established biomarkers are not easily available in the primary care setting. A growing body
of literature is focused on identifying additional non-invasive early signs of AD. The aims
of this program of research were to understand factors contributing to the AD diagnosis
variability in primary care settings and methods to improve early diagnosis by primary
care providers. Four studies were undertaken to achieve these aims. The first study reported the results of an integrated review estimating the prevalence of missed diagnosis
in primary care when compared to trained raters’ diagnoses. The findings call to attention
the difficulty primary care providers face to detect and diagnose AD at all levels of the
healthcare system. This led to the second study. Chronic pain is a common comorbid ailment seen in those with AD and often is a driving factor of patients seeking medical care.
In order to understand the pain experience in those with worsening cognition, the second
study was a secondary analysis of a cross-sectional age- and sex-matched two group cohort study and found that the experience of pain differs between males and females as a
measure of cognition worsened suggesting a possible role of pain as a tool to distinguish
those at risk for AD. This finding led to the third study, which was a narrative review conducted to describe how alterations in senses have been associated with the diagnosis of
AD. The results suggested differences in smell, taste, vision, hearing, and proprioception
were associated with different levels of the AD continuum but points out an obvious gap
in the literature concerning other senses. This led to the fourth study examining evidence
that the ε4 allele of Apolipoprotein E modifies the experience of pain in those individuals
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carrying the allele such that greater temperatures are required to elicit pain and the experience of that pain is more unpleasant. Additional studies should expand on the results of
this pilot study.
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Chapter 1
Introduction

Background
An estimated financial benefit of $7 trillion can be expected to the United States health care
system if 70% of those with Alzheimer’s disease (AD) are diagnosed (“2020 Alzheimer’s
disease facts and figures” 2020). Since first described in 1907 by Alios Alzheimer, who
noted the presence of abnormal fibrous inclusions within the cytoplasm of pyramidal neurons of a 50 year old age woman, the presence of these "hallmarks" of AD on autopsy
remains the only definitive means of diagnosis of AD (Hippius and Neundorfer, 2003).
Current estimates suggest that half of the 5.8 million Americans age 65 and older living
with AD are undiagnosed (“2020 Alzheimer’s disease facts and figures” 2020). Primary
care providers (PCPs) have been identified as key to improve earlier recognition of AD,
though, there is evidence suggesting a lack of confidence in their own diagnostic skills
and care management (“2020 Alzheimer’s disease facts and figures” 2020).
In the primary care setting AD presents variably with subtle changes over the course
of months to years and PCPs find it difficult to recognize these early symptoms in patients
(Knopman, Donohue, and Gutterman, 2000; Martin, Kelly, et al., 2015). Many providers
wrongly misattribute small changes in cognitive function as a process of normal aging
(Knopman, Donohue, and Gutterman, 2000). Timeliness of diagnosis has been shown to
vary from 18 to 30 months, and in some cases, up to four years (Dubois, Padovani, et al.,
2016). There is evidence of variation in the ability of primary care providers to consistently
detect and diagnose AD (Bradford et al., 2009). A lack of specialty services available is a
common complaint amongst PCPs when surveyed on the difficulties of care for patients
with AD (Bradford et al., 2009).
Interventions to improve diagnosis have seldom focused on overcoming the barriers identified in previous studies and the effects of interventions aimed at improving diagnosis are limited (Iliffe, J. Wilcock, et al., 2010; Koch and Iliffe, 2011). The results of empirical studies aimed to evaluate interventions to improve early diagnosis have been limited
(Koch and Iliffe, 2011). Educational interventions, focusing on improving care through
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seminars, workshops, small-group learning, and decision support software found no evidence of improved diagnosis between intervention or control groups (Koch and Iliffe,
2011). The service based interventions of initiating dementia case-managers did not show
increased rates of diagnosis (Koch and Iliffe, 2011). An in-home assessment by a specialist
nurse only increased diagnosis by 20% (Perry et al., 2008).
PCPs are advised to focus on the evaluation of the clinical consequences of AD,
using clinical assessment and the results of neuropsychological testing, to diagnose AD.
This does not incorporate the currently widely held understanding of AD which includes
measures of biomarkers (Jack et al., 2018; Tolea and Galvin, 2013). As the majority of older
adults with AD are diagnosed by their PCP, focus should be paid to understanding how
primary care providers view the diagnosis of AD and what tools or resources can be made
available to them to improve their diagnostic abilities (“2020 Alzheimer’s disease facts and
figures” 2020).

Theoretical Framework
The National Institute on Aging (NIA) developed a framework for the diagnosis of AD
that has shifted idea of AD as a collection of clinical consequences and towards a biological
process that incorporates measurable physiological parameters or biomarkers (Jack et al.,
2018). Current biomarkers of AD are grouped into those of beta amyloid deposition (A),
pathologic tau (T), and neurodegeneration (N) and are typically gathered by advanced
imaging and lumbar puncture to obtain cerebrospinal fluid (Jack et al., 2018).The NIA
framework describes how variation of biomarker profiles can be used to diagnose those
with AD and highlights the alterations of biological processes occurring during a preclinical phase or before disease is recognized clinically. The earliest markers of AD which can
be detected at least 10-20 years before the onset of clinical symptoms are the depositions
of Aβ as measured with advance neuroimaging and within the cerebrospinal fluid (Long
and Holtzman, 2019).
Aβ peptides are produced by the sequential cleavage of β-amyloid precursor protein by β-secretase enzyme and γ-secretase into smaller units (Long and Holtzman, 2019).
Aβ peptides are prone to aggregate to form oligomers, protofibrils, and fibrils. The Aβ42
oligmer has a greater propensity to aggregated and can be found at the center of synthetic
amyloid plaques (Long and Holtzman, 2019). There is evidence of Aβ uptake by microglia
and intracellualr seeding in a prion-like manner leads to aggregation of oligomers leading to the amyloid plaques visible on autopsy (Long and Holtzman, 2019). Although not
proven, the deposition of Aβ is thought to be the initiating steps of AD pathology supported by evidence that in genetic forms of AD there is an increase in Aβ42, Aβ production,
and Aβ fribrillinogenic properties (Long and Holtzman, 2019). Additionally, the strongest
genetic risk factor for AD, apolipoprotien E (APOE) influences Aβ seeding and clearance
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(Long and Holtzman, 2019). The aggregation and deposition of Aβ is thought to cause
down stream effects leading to AD (Jack et al., 2018; Long and Holtzman, 2019).
Aβ deposition may be required for the progression of tau pathology in AD as tau
pathology does not progress without co-occurring amyloid pathology, and the rate of amyloid accumulations predicts onset of tau accumulation (Long and Holtzman, 2019). In AD
tau propagates throughout the AD brain in a stereotyped fashion and can be classified
using the Braak staging (Braak et al., 2003; Long and Holtzman, 2019). The tau protein
is associated with microtubule assembly, stabilization of neuronal axons and microtubule
transport (Long and Holtzman, 2019). Hyperphosporylated tau tends to aggregated and
fibrilized. The pattern of tau misfolding in AD is different to other tau pathologies (Long
and Holtzman, 2019). Tau is measured in cerebral spinal fluid (CSF) and with Tau PET
imaging (Jack et al., 2018).
Tau pathology may lead to neurodegeneration (Jack et al., 2018). Brains of those
with AD show cerebral cortical atrophy which does not involve the frontotemporal cortex and spares primary motor, sensory, and visual areas (Risacher and Saykin, 2013). AD
pathology also leads to symmetrical dilation of the lateral ventricles with significant atrophy of the hippocampus and dilation of the adjacent temporal horn of the lateral ventricle
(Risacher and Saykin, 2013). Biomarkers of neurodegeration have many causes and are
not associated with neuropathological findings used to diagnose AD (Jack et al., 2018).
Measures of neurodegeneration together with amyloid and tau measures are better at predicting cognitive decline than amyloid studies alone (Jack et al., 2018).
The cut point for each AT(N) biomarker describes eight different AT(N) biomarker
profiles that can help to assign individuals into one of three categories 1) individual with
normal AD biomarkers, 2) those in the AD continuum, and 3) those with normal amyloid but abnormal T or (N) (Jack et al., 2018). For those in the AD continuum he clinical
progression of AD is understood to be on a continuum starting with preclinical AD and
progressing to mild cognitive impairment (MCI) due to AD, and finally dementia due to
AD (Jack et al., 2018). During the preclinical phase of AD clinical symptoms such as memory loss are not apparent but early markers of AD are beginning to be present. Persons
with MCI due to AD experience mild symptoms that do not interfere with everyday activities and typically demonstrate biomarker evidence of AD (Jack et al., 2018). The final
phase on the AD continuum is dementia due to AD which can be further categorized into
mild AD, moderate AD, and severe AD (Jack et al., 2018). The time patients spend in
each phase varies and maybe affected by age, genetics, gender, as well as other factors
(“2020 Alzheimer’s disease facts and figures” 2020) . Further, 15-38% of those with MCI
may progress on to AD while others remain stable and few may revert back to normal
cognition, the reasoning is not understood (“2020 Alzheimer’s disease facts and figures”
2020.
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Aims
The overall aims of this program of research were to understand factors contributing to
AD diagnosis variability in primary care practice settings and to find ways to improve
early AD diagnosis by primary care providers. Four projects were undertaken to meet the
aims and each resulted in a published manuscript.
The first project sought to describe the current evidence available to identify health
care system factors that contribute to missed or delayed diagnosis of dementia by primary care providers through an integrative review of empirical studies identified through
a systematic electronic search of the scientific literature databases (3. Romano R. R., Carter,
Anderson, et al., 2020). The results were published in the Journal of the American Association of Nurse Practitioners. There was considerable variation in the diagnostic accuracy of
dementia that could be attributed to barriers at the organizational, provider, and patient
level.
The second project was published in the Journal of Alzheimer’s Disease and compared
the association between psychophysical responses to experimental thermal pain in males
and females to determine if sex differences in pain exist across the cognitive spectrum
(R. R. Romano et al., 2019). A secondary analysis of data from an age-and sex-matched between groups cross-sectional study suggested evidence that patterns of response to painful
stimuli may differ between males and females with worsening cognition.
The third project was published in Biological Research for Nursing and was a narrative
review of a systematic search of the scientific literature describing how sensory changes
have been used as biomarker for AD (3. Romano R. R., Carter, and T. B. Monroe, 2020. The
review found the most widely studied sensory system was olfaction and that changes in
sense of smell, taste, vision, proprioception, and hearing are different between those with
AD, MCI, or normal cognition.
The final project, which has been accepted for publication in Journal of Alzheimer’s
Disease, compared responses to painful thermal stimuli based on APOE e4 allele status. As
far as we know this is the first manuscript to make this comparison and we were able to
demonstrate that those with an APOE e4 allele were statistically more likely to experience
a greater level unpleasantness of pain when compared to those without the epsilon4 allele.
These four projects have provided a foundation for continuation in searching for
ways in which research can assist primary care providers to improve their care to people
living with AD and their families. The ultimate goal would be to identify those with AD
or at least a high probability of developing AD well prior to the onset of symptoms.
The following four chapters provide the results of the projects that were undertaken for this dissertation. The chapters move from examining the practice characteristics
that are related to primary care providers initiating screening, through the use of thermal
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responses across the cognitive spectrum, to understanding sensory changes to as potential biomarkers, and culminating with the differences in individuals with different APOE
genes.

6

Chapter 2
Factors Influencing Dementia Detection in Primary
Care Setting 1

Background
Alzheimer disease (AD) is the most common type of dementia and is estimated to affect
over 5.7 million adults in the United States (Association, 2018). Alzheimer disease and
other forms of dementia are often not detected until advanced stages of the disease because there is currently no definitive method for diagnosing AD except through direct observation of the brain after death (Association, 2018). Clinical symptoms of AD typically
begin with subtle short-term memory problems or slight personality changes (Wilson et
al., 2012), making early diagnosis difficult. Epidemiological studies suggest that at least
half of the people living with AD have not yet received a diagnosis (Barker et al., 2002).
The prevalence of AD is expected to triple over the next 30 years (Hebert et al.,
2013; Patterson, 2018). Estimated health care costs of AD in the United States were $277
billion for 2018 and are estimated to surpass $1.1 trillion by 2050 if there is no change in
preventing or delaying AD (Association, 2018). Estimates suggest that slowing disease
progression by at least 5 years is estimated to reduce the overall mortality rate, financial
costs, and public burden related to AD by 39% (Zissimopoulos, Crimmins, and St Clair,
2014).
Less than half of persons with dementia and/or their caregivers report any history
of clinical cognitive evaluation (Kotagal et al., 2015). One reason for low reports of receiving a cognitive evaluation is that the United States Preventive Services Task Force does
not currently recommend screening for cognitive impairment in older adults, arguing that
there is insufficient evidence to support the benefit of early detection particularly in light
of ineffective treatment (Moyer and Force, 2014). However, the lack of effective treatment
1 Reprinted

from the final submission with permission. Romano R,R., 3rd, Carter M.A., Anderson A.R., et
al.. An integrative review of system-level factors influencing dementia detection in primary care. J Am Assoc
Nurse Pract. 2020;32.4, pp. 299–305. https://doi.org/10.1097/jxx.0000000000000230.
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may be changing because ongoing studies are testing novel drugs and non-drug therapeutic interventions that may help prevent the onset or delay the progression of the disease
(Cummings et al., 2019) and current pharmacological and non-pharmacological interventions seem to be most beneficial during the earliest stages of AD (Robinson, Tang, and
Taylor, 2015). Thus, early recognition of AD is critical for current and future treatment
effectiveness.
There are other reasons that nurse practitioners (NPs) and other primary care providers may not screen for AD. One reason contributing to limited screening for AD results
from health care system factors minimizing the need for this service. For example, health
care system models may constrain NP’s practice behavior by failing to recognize how important early diagnosis is to individuals with AD and their families. Andersen’s behavioral model of health service utilization suggests that environmental characteristics influence behavior (Andersen, 2008; Andersen, 2008). This model proposes the importance of
understanding the relationships between environmental characteristics and screening behaviors by NPs caring for people with AD and their families. Future studies focused on
improving screening behaviors must consider these environmental characteristics when
designing, implementing, and evaluating the behavior-change intervention.
An older survey of 741 caregivers of people with AD found that 74% of families
first approached their primary care provider with concerns about the memory of their
loved one (Wilkinson et al., 2004). However, in the same study the authors found that
in 70% of the cases, the diagnosis of AD was made by someone other than their primary
care provider (Wilkinson et al., 2004). To our knowledge, this is the most recent study to
address this phenomenon.

Objective
The overall goal of this literature review was to better understand why NPs may not routinely screen patients for AD. The specific objective was to identify factors in primary care
practices reported in the literature that influence missed or delayed diagnosis of cognitive
impairment. Understanding these factors will assist NPs in providing optimal care to patients with AD and their caregivers. Early detection of cognitive changes is necessary to
trigger further evaluation leading to a formal diagnosis. This is not only critical to diagnosing dementia, but also for uncovering reversible causes of cognitive decline such as
normal pressure hydrocephalus, thyroid disease, vitamin deficiency, or depression.

Methods
Studies were searched electronically through MEDLINE (OVID interface, 1948 onwards),
the Cochrane Central Register of Controlled Trials (Wiley interface, current issue), CINAHL,
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and PsycINFO. The search strategy aimed to find peer-reviewed manuscripts that identified organizational, provider, or patient characteristics of the primary care setting that
influenced screening in AD. A combination of three terms, “dementia” and “diagnosis”
and “primary care,” were used plus four purposefully selected search terms - “barrier,”
“attitude,” “organizational factors,” and “missed diagnosis”- were used in each electronic
search. All potential English-language manuscripts were exported directly to EndNote.
Manuscripts were considered for inclusion if they met the following criteria: 1. They
were empirical studies; 2. They identified factors for missed or delayed diagnosis; 3. They
included a comparison of diagnostic accuracy by primary care providers; or 4. They identified organizational characteristics related to diagnosis of AD. Manuscripts were excluded
for the following criteria: 1. They were not published in English; 2. They were reviews or
commentaries; or 3. Full articles could not be obtained.
First, all duplicates were removed. Next, articles that were not topically related
based on title and subsequent reading of the abstract were excluded. And third, articles
that met the above exclusion criteria were removed (Figure 2.1).
A piloted data collection form was developed and revised to capture consistent information to address the research objective. The data collection form included information
on: the estimated prevalence of dementia in the sample, the accuracy of provider diagnosis
including cognitive impairment, dementia, Alzheimer’s disease, vascular dementia, other
diagnosis; the tools used by the provider to make an estimation of cognitive impairment;
and the tool used to determine accuracy in diagnosis. Additionally, the form collected
textual data on any factors identified that contributed to the diagnosis of AD or a related
dementia. The overwhelming majority of the literature focused on “Alzheimer’s Disease”
or “dementia” and for the purposes of this paper we elected to use the term AD because
it is the most common sub-type of dementia and there are specific diagnostic criteria for
probable or possible AD.
Risk of bias in the remaining studies was assessed using design specific tools developed by the Risk Assessment Work Group of the National Heart, Lung, and Blood Institute
(Study Quality Assessment Tools, 2020). The ratio was calculated for each study between
point values (e.g., No= 0, Yes=1, Good=2, Fair=1, Poor=0) assigned for each item to total
number of questions. Each author reviewed the scoring criteria and a final score consensus
was reached by all authors.
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Results
The search yielded 140 empirical studies. Of these, 133 studies were excluded because they
focused on the validation of specific screening tools, the detection of other illnesses, or dementia care outside primary care. This resulted in seven articles selected to be included
in the literature review: two were interventional studies, two were case-comparison studies, and three were cross-sectional studies (Table 2.1). None of these studies examined NP
practices specifically and it is likely that few, if any, NPs were included in the sample. A
comparison of study characteristics is provided in Table 2.1. Most studies were rated as
high quality, with the weakest study receiving a calculated score of 0.52 (range 0-2) using
the bias risk tool described above (Table 2.2. The major threat to internal validity was
selection bias across all studies as most studies relied on non-random methods to select
participants. A description of internal threats to validity are presented in Table 2.2.
The studies estimating diagnostic accuracy after intervention are summarized in
Table 2.3. Two studies compared the provider’s clinical judgment against a neuropsychological test battery, while one study compared clinical diagnosis to autopsy results.
Prevalence estimated by clinicians ranged from 6-51% and the accuracy of diagnosis was
between 19-81%. Identifying factors contributing to the detection of dementia are summarized in Table 2.4.
The most widely cited organizational barrier was lack of services, while the most
widely cited provider barrier was lack of the provider’s ability to accurately make the
diagnosis. A frequently noted patient barrier to accurate diagnosis of dementia was the
occurrence of confounding comorbidities or frailty.
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Table 2.1: A descriptive comparison of studies.
Author

Country

Population

Venezian (2016)
Magin (2016)
Edwards (2015)

Italy
Australia
England

Tierny (2014)

Canada

Fortinsky (2010)

USA

Provider
Patients
Providers
Care Staff
Providers
Patients
Providers

Boustani (2005)

USA

Mok (2004)

USA

N

Study Type

Theme

131
489
28
62
13
133
422

Cross-sectional
Cross-sectional
Intervention

Knowledge of AD
Attitudes towards AD
Improve patientcentered outcomes
Accuracy of diagnosis

Patients

3340

Patients

463

Quality
improvement
Case comparison

Case comparison
Cross-sectional

Geographic variation
& barriers
Implementing screening
protocol
Accuracy of diagnosis

Table 2.2: Descriptive comparison of studies quality.
Author (Year)

Quality
Score*

Threats to Internal Validity

Cross-Sectional
Veneziani (2016)

0.76

Magin (2016)
Fortinsky (2010)
Case-comparison
Tierney (2014)

0.79
0.83

Mok (2004)

0.80
0.91

Interventional
Edwards (2015)

0.75

Boustani (2005)

0.52

*

History threat (other surveys), selection bias (younger females),
social desirability
Selection bias (non-random sample, selected by receptionist)
Possible selection bias (39% response rate)
Selection bias (non-random sample)
Selection bias (non-random selection of participants),
maturation bias (better able to access autopsy)
Potential testing bias (pre-test cues), Potential maturation bias
Instrumentation bias (false negatives not accessed, no clinical data support),
selection bias (large number did not participate)

Ratio of the total score determined using NIH study quality assessment tools and the number of items
assessed. Author consensus reaching in support of scoring.

Table 2.3: Descriptive comparison of accuracy of dementia diagnosis.
Study

Provider Method

Referenced Method

Tierney (2014)
Boustani (2005)

Clinical judgment
Clinical judgment

Mok (2004)

Clinical diagnosis

Neuropsychological test battery
6-item screener, CSI-D
CERAD battery, GDS
semi-structured interview
Autopsy

Prevalence

Accuracy

30%
6%

60.6%
18.5%

51%

81.2%
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Table 2.4: Factors identified contributing to detection and care of
dementia.
Factors
Organizational
Location
Time
Lack of services
Lack of specialists
Lack of support staff
Lack of reimbursements
Patient load
Provider
Gender
Education
Attitudes
Testing process
Communication
Patient
Age
Gender
Severity/Risk/Comorbidities
Awareness
Attitudes

Veneziani
(2016)

Magin
(2016)

Edwards
(2015)

Tierney
(2014)

Fortinsky
(2010)

Boustani
(2005)

Mok
(2004}

X
X
X
X

X

X
X
X

X
X

X
X
X

X

X

X
X

X
X
X
X
X

X
X
X

X
X

X
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Discussion
This review of research literature suggests that the clinical presentation of dementia is heterogenous and results in variation in diagnostic accuracy. Results indicate that primary
care providers have varying ability to accurately diagnose AD irrespective of education
and training (Association, 2018; Mok et al., 2004; Tierney et al., 2014). The study by Mok et
al., 2004 suggested that diagnostic accuracy was 84% when confirmed via autopsy among a
group of community based primary care providers. Similarly, Tierney et al., 2014 reported
the specificity of clinical judgment to detect AD was 86% in primary care providers. Tierney et al., 2014 concluded that many provider and patient characteristics influenced the
likelihood of detecting dementia, and that providers seeing a greater number of cognitively impaired individuals demonstrated better clinical judgment. The authors further
noted that overall complexity of dual comorbidities heavily influenced diagnostic accuracy (Tierney et al., 2014). The ability to accurately discern cognitive impairment was not
associated with routinely conducting cognitive assessments on individuals with positive
family history or frequently asking about cognitive function on exam (Tierney et al., 2014).
Similarities in the results from Mok et al., 2004 and Tierney et al., 2014 suggest that
organizational need, such as higher patient burden, may be a greater factor influencing
accuracy in diagnosis and may be an influencing factor on practice behavior. No intervariable correlations were presented by Tierney et al., 2014 but it may be possible that NPs
will increase their screening for AD as the number of patients with dementia in the practice
increases.
Provider educational needs have been identified as a major factor at both the provider
and patient level to diagnosis of AD (R. Edwards, Voss, and Iliffe, 2015; Fortinsky et al.,
2010H; Martin, Fleming, et al., 2015; Veneziani et al., 2016). Provider attitude towards
dementia care and treatment are also major factors influencing the accurate detection and
diagnosis of dementia (Table 2.4). An educational intervention developed for primary care
providers showed an improvement on pre-test versus post-test measures on both knowledge and attitudes, suggesting that knowledge is necessary to improve attitudes (R. Edwards, Voss, and Iliffe, 2015).
Although improvements were seen on overall attitude scores, providers continued
to associate lack of diagnosis with lack community support and services (R. Edwards, Voss,
and Iliffe, 2015). In a different study, the provider practice of referring patients with cognitive impairment to community support services varied by geographic location, further
suggesting that organizational factors contribute to the detection and care of dementia
(Fortinsky et al., 2010H).
Magin et al., 2016 reported that the majority of patients would like to be tested
for dementia. However, lack of comfort communicating with patients about dementia
and disclosing diagnosis was found by Veneziani et al., 2016 to be a contributing barrier
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to diagnosis. Interestingly, Veneziani and colleagues found that the routine practice of
administering cognitive screening tests did contribute to overall knowledge and attitude
about dementia (Veneziani et al., 2016). Additionally, results found by Tierney et al., 2014,
found that routine cognitive screening does not contribute to the ability of providers to
accurately discern pathological cognitive impairment.
Findings by Boustani et al., 2005 support that a screening protocol alone is not sufficient to improve identifying patients with AD. In a practice with a prevalence of 6%
dementia, less than half (47%) of the patients with dementia were identified by a screening
protocol. The researchers concluded that a more complex intervention may be warranted.
This intervention should consider all levels of the health care system (Boustani et al., 2005).

Gaps in Literature
We found no study that explicitly measured data related to organizational characteristics
such as staffing levels. Only one study explored self-reported organizational level factors
including reimbursement, time constraint, and community resources and did not conduct
an objective, independent assessment of these factors (Fortinsky et al., 2010H). Review
findings suggest that organizational and environmental characteristics contribute to detection and care of dementia, yet no study directly used organizational structures as the
main predictive variable.
A larger gap exists in the evidence to understand the reasons behind discordant
diagnosis, although education is constantly cited as the reason. Educational needs are an
obvious barrier, although Veneziani et al., 2016, did not find an association between year
of graduation of the provider and attitude or knowledge. However, other studies have
demonstrated this relationship (Boise et al., 1999; Boise, 2006; Bradford et al., 2009). The
lack of association in the Veneziani et al., 2016, study may be the result of selection bias
and lack of generalizability as the sample was drawn from a research network (Veneziani
et al., 2016). In addition, only three studies identified in this literature search explored how
electronic health record decision support systems impacted dementia care and diagnostic
accuracy (Chou et al., 2012; Eichler et al., 2014; Grypma, 2007).

Limitations
The future goal of this work is to inform research about how AD screening can be implemented and evaluated by primary care NPs. This review has three main limitations. The
first limitation is that one researcher conducted the literature search, review of articles, and
extraction of data. To minimize this limitation, the reviewer adhered to a coding sheet and
revisited articles after any edits were made to the coding sheet. Also, the authors used a
published quality scale and reached consensus in the evaluation of each study, helping to
reduce bias in the results.
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The second limitation is the heterogeneity of diagnosis and prevalence across the
articles. We did not attempt to control for this heterogeneity, therefore, interpretation of
diagnostic accuracy may be skewed. Not surprisingly, the majority of articles focus on
AD or “dementia” with little attention given to the diagnosing specific sub-types of dementia. However, this limitation is overcome by the overwhelming majority of dementias
presenting with some form of pathologic cognitive impairment, which is a key component
to accurate diagnosis. The third limitation is that none of the articles reported whether or
not NPs were included in the sample or how NP practices might be different from other
providers. Multiple studies have reported that NPs and physicians have similar practice
outcomes, but this may not hold for screening for AD (Stanik-Hutt et al., 2013).

Conclusions
Primary care providers, and especially NPs, are the first point of contact for patients and
families with concerns about memory loss. At the same time, patients presenting to health
care settings with memory complaints tend to not perform well on cognitive measures
(Kumar, Singh, and Ekavali, 2015). As the prevalence of AD is expected to increase and
new, effective treatments are developed, there is a need to develop primary care services
that detect AD earlier (Hebert et al., 2013). Dementia in general is under diagnosed, and
major initiatives in the United States are aimed at improving diagnosis. For example, the
National Institute on Aging in the National Institutes of Health has very useful materials
on assessing cognitive impairment (Association, 2018), and a required part of Medicare’s
Annual Wellness Visit includes an assessment of cognition. The results of this review,
however, suggest that solely implementing a screening protocol is not enough to improve
identification of AD.
NPs are poised to be the frontline leaders in screening for pathologic cognitive
impairment as well as previously mentioned known reversible causes of cognitive impairment (e.g., thyroid hormone alterations, normal pressure hydrocephalus, vitamin deficiency, severe depression, and adverse effects from some medications). Better knowledge by providers of reversible causes of cognitive decline could help address patient and
provider level discomfort in diagnosing AD or a related dementia only addresses one component of the issue. Importantly, findings from the current review indicate that additional
interventions that improve support systems, increase services for individuals with AD and
their families, and clarifying testing procedures may be a more critical step in achieving the
goal of earlier diagnosis. Finally, evidence presented in this review suggests that organizational and environmental factors exist that influence provider practice, and thus screening
and diagnosing of dementia in primary care and these factors need to be explored further.
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Chapter 3
Cognitive Function with Perceptions of Pain: Sex
Differences in Seniors1

Introduction
Nearly 50 million adults worldwide over the age of 65 years will develop dementia (Hebert
et al., 2013; Patterson, 2018), and amongst those, an estimated 50-93% will experience
chronic pain (Abdulla et al., 2013; Corbett et al., 2014; Stubbs et al., 2016; Kooten et al.,
2015). Dementia is a known risk factor for the under-treatment of pain (T. B. Monroe,
Carter, et al., 2013; T. B. Monroe, Gore, Chen, et al., 2012; C. M. Paulson, T. Monroe, and
Mion, 2014; Stubbs et al., 2016). People with Alzheimer’s disease (AD) receive less pain
medication for similarly painful conditions when compared with cognitively intact older
adults (Haasum, Fastbom, Fratiglioni, Kareholt, et al., 2011; Haasum, Fastbom, Fratiglioni,
and Johnell, 2012). Pain is a multidimensional experience arising from cognitive, sensory
and affective central nervous system processes involving multiple neuronal circuits and
brain regions.
Furthermore, AD impacts brain structure, such as the hypothalamus and the prefrontal cortex which is responsible for affective pain (Cole et al., 2006; A. K. Jones, Kulkarni, and Derbyshire, 2003; Scherder, Sergeant, and Swaab, 2003; Stubbs et al., 2016). A
potential cause of the under-treatment of pain in dementia patients is the lack of understanding about how dementia influences the psychophysiological factors of the pain experience (Stubbs et al., 2016) and how these influences differ by sex in communicative people
across the cognitive spectrum. Pain is the primary reason people seek medical attention,
and more evidence is needed to understand the altered pain experience in AD patients as
the prevalence of Alzheimer’s disease and related dementias is expected to triple over the
next 30 years (Hebert et al., 2013; Johannes et al., 2010; Patterson, 2018).
1 Reprinted

from final submission. Romano, R.R., Anderson, A.R., Failla, M.D., Dietrich, M.S., Atalla, S.,
Carter, M.A., Monroe, T.B., Sex Differences in Associations of Cognitive Function with Perceptions of Pain in
Older Adults, 715-722., Copyright (2019), with permission from IOS Press. The publication is available at IOS
Press through http://dx.doi.org/10.3233/JAD-190142
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Psychophysical studies of pain frequently report sex-related differences in the pain
experience in cognitively healthy adults (Fillingim et al., 2009; P. E. Paulson et al., 1998;
Straube et al., 2009). These sex differences may change with age since the prevalence of
chronic pain increases with age as the function of endogenous pain inhibitory systems
declines (R. R. Edwards, Fillingim, and Ness, 2003; Naugle et al., 2013; Riley et al., 2010). In
cognitively healthy older adults, women tend to experience pain at a higher intensity and
report pain more frequently than men (Johannes et al., 2010; Leveille et al., 2005). However,
this relationship has not been demonstrated to exist across the cognitive spectrum.
Understanding patterns of pain responsivity across age, sex, and cognitive ability
are essential given evidence of sex-associated differences in the psychophysical and neuropsychological processing of pain, the increased incidence of chronic pain in older adults,
and the potential for undertreatment of pain in dementia. We have published several papers from the parent data set showing sex differences in cognitively healthy older adults
(T. B. Monroe, Fillingim, et al., 2018). We have also shown sex differences in a pilot sample of people with dementia only (Cowan et al., 2017). To extend upon this work, we
now examine sex differences in pain across the cognitive spectrum. While several between
groups psychophysical studies on sex-differences in pain appear in literature, there is a
paucity of experimental pain research using a continuous measure of cognitive ability to
predict pain outcomes across the cognitive spectrum. Understanding patterns of experimental pain responsivity across age, sex, and cognitive ability are essential given evidence
of sex-associated differences in the psychophysical and neuropsychological processing of
pain. This understanding may help to develop more effective treatment plans for the growing number of older adults experiencing chronic pain with comorbid dementia. Thus, we
tested the hypothesis that sex-differences in psychophysical processing of pain are significantly associated with increasing or decreasing levels of global cognition.

Methods
Study Design
This study is a secondary analysis of a cross-sectional parent study designed to compare
the psychological response to thermal pain in older adults with and without dementia.
Thus, the current methods have been previously published (Cowan et al., 2017; T. B. Monroe, Beach, et al., 2017). The purpose of the current study was to examine sex differences
in the association of cognitive impairment and thermal pain perception in verbally communicative older adults. Cognitive impairment, as assessed by the MMSE (range 0-30),
was used as the primary co-variate in our outcome analysis and included scores across the
cognitive spectrum (no cognitive impairment to severe cognitive impairment).
The Vanderbilt University Institutional Review Board approved the parent study,
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and each participant, or legal surrogate when appropriate, provided written informed consent at the time of enrollment. Capacity to consent was assessed using the University of
California San Diego Brief Assessment of Capacity to Consent (UBACC), that takes less
than 5 minutes to complete. A UBACC score higher than 14.5 was required for informed
consent, as this cut-off is 89% sensitive and 100% specific for determining capacity to consent for research (Jeste et al., 2007). Individuals with UBACC scores less than or equal to
14.5 (i.e., those lacking decisional capacity) signed an assent document and a legal surrogate provided consent. All participants and legal surrogates who completed the study
were compensated US$100 for their time.

Participants
The recruitment and enrollment protocol of the parent study are previously published
(Cowan et al., 2017; T. B. Monroe, Beach, et al., 2017). Participants 65 years of age or
older were recruited from the greater Nashville, Tennessee metropolitan area and enrolled
over three years from 2012 to 2015. A clinical diagnosis of AD was verified based on
documentation in the medical record of 1) neuropsychiatric evaluation, diagnostic MRI or
PET, lack of other potential causes of memory loss; and 2) results of the evaluation with
the MMSE, Montreal Cognitive Assessment or the Functional Assessment Staging Scale.
Cognitively healthy participants were recruited using a mass email, flyers, and recruitment
presentations in healthcare facilities and local events.
Participants were excluded for the following reasons: the presence of a chronic pain
diagnosis, daily use of opioid or non-opioid pain medication, upper extremity peripheral neuropathy, any current cancer diagnosis or treatment, previous stroke with residual deficit, Raynaud’s Disease, unstable cardiac conditions, insulin-dependent diabetes, or
current diagnosis of major depression.
Because the parent study included neuroimaging, additional exclusion criteria included claustrophobia, the presence of a pacemaker, ventricular shunt, or any implanted
metal object not confirmed as 3 Tesla MRI compatible, multiple metal implants in the same
extremity, or presence of movement disorders (e.g., Parkinson’s disease, Restless Leg Syndrome). Participants were required to be verbally communicative and able to provide a
verbal pain rating.

Screening and Enrollment
A two-part screening process included an initial telephone screening, followed by a onehour visit to confirm eligibility either at the participant’s place of residence or at the Vanderbilt University Medical Center. Before any data collection occurred participants and the
legal surrogate (when necessary) were allowed to experience the thermal pain stimulus
and complete two practice psychophysics trials. Practice trials ensured that participants
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understood the directions and could respond appropriately. Evidence of an appropriate
response included the ability to follow directions and vocalize pain.

Measures
A trained research assistant administered all study measures orally to participants to decrease subject and caregiver burden and to minimize missing data. Demographic measures included a detailed list of all medications and the Hollingshead Four-Factor Index
of Socioeconomic Status (SES) (Hollingshead, 1975). The Brief Pain Inventory Short Form
(BPI-SF) was used to collect current and average daily pain (Cleeland and Ryan, 1994).
Depression and anxiety screens included the Geriatric Depression Scale-Short Form (GDS15) (Kurlowicz, 1999) and the state and trait forms of the Spielberger State-Trait Anxiety
Inventory (STAI) (Spielberger, 1971), respectively.

Thermal Stimulation Protocol
Trained research assistants administered the psychophysical thermal stimulation assessment over approximately 30 minutes following a modified protocol of the experimental
mechanical pressure pain protocol by Cole et al., 2006. Two aspects of pain were assessed
using the Medoc Pathway Pain and Sensory Evaluation System: the intensity, how strong
the pain feels; and the unpleasantness, how unpleasant or disturbing the pain feels. A 30
x 30 mm Medoc thermode was attached to the thenar eminence of the right hand. The
thermode was programmed to deliver a baseline temperature of 30ºC with increasing heat
at a rate of 1 ºC/s (max temperature = 48 °C).
Participants were instructed to signal to stop the increasing heat when the participant felt ‘warmth,’ ‘mild pain,’ or ‘moderate pain. The temperatures at which each participant stopped the increasing heat at each percept were documented. Following the approach we have previously published (Cowan et al., 2017; T. B. Monroe, Beach, et al., 2017),
pain intensity was evaluated using a 0-20 sensory numeric rating scale (Figure 3.1) with anchors “warmth=0,” “mild pain=5,” and “moderate pain=11.” Unpleasantness was evaluated using a 0-20 unpleasantness scale with anchors “0=neutral,” “5=slightly unpleasant,”
“8=unpleasant,” “11=very unpleasant,” “16=intolerable,” and “20=extremely distressing.”
Participants were acclimated to the scales and then completed three trials at each temperature condition, and the average self-reported pain intensity and unpleasantness ratings
across the trials used in our analyses.

Statistical Analysis
Participant characteristics and study data collected on a continuous scale were summarized using median and inter-quartile range (IQR) due to lack of normality (Fischer test
> ±2.58). Frequency distributions summarized nominal and ordinal data. Comparisons
between males and females were conducted using Mann-Whitney U tests (continuous)
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Figure 3.1: Numerical descriptor scale used to measure affective
unpleasantness and sensory intensity. Reprinted from Eur J Pain, 9,
Petzke F, Harris RE, Williams DA, Clauw DJ, Gracely RH, Differences in
unpleasantness induced by experimental pressure pain between patients
with fibromyalgia and healthy controls. 325–335. Copyright (2005), with
permission from John Wiley and Sons.
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and Chi-Square Tests of Independence (nominal, ordinal). Cohen’s d effect size indices
were generated to summarize the magnitude of the gender effects. Associations of global
cognition (MMSE scores) with the psychophysical reports (temperatures and ratings of
unpleasantness) for males and females were generated using Pearson correlations. Differences between males and females in the strength and/or direction of those associations
were tested using linear regressions. Each of the gender and MMSE distributions were
mean centered and multiplied to create an interaction term that was entered into each regression, along with gender and MMSE as main effects, to test for differences between
males and females in the association of MMSE with the respective psychophysical report
used in the regression.
Before conducting these correlations and regressions, the skewed psychophysical
distributions were transformed to normal. Such that at the warmth threshold, both temperature and unpleasantness values were rank transformed and at the mild and moderate
pain thresholds, unpleasantness values were square-root transformed. For all analyses, a
maximum alpha of 0.05 (p < 0.05) was used for determining statistical significance.

Results
Demographics
A total of 80 participants were in the parent study. For this analysis, three participants
were excluded due to an MMSE score of less than 10 and one subject was excluded due to
missing an MMSE score. The final sample consisted of males (N=38) and females (N=38)
with a median age of 73 (IQR: 68-80). MMSE scores (Table 3.1) ranged from 11 to 30 (IQR:
20-30). Of the sample 84% were white. On the day of the study, very few participants
reported any pain (median both average and now = 0) and fewer than 10% reported pain
levels of greater than 2 (7 of 76, 9%). There were no statistically significant differences
between males and females on any of the participant characteristics investigated including
most importantly the distribution of MMSE scores (Table 3.2).

Psychophysical
Summaries of the psychophysical self-report data for males and females are in Table 3.3.
Females reported mild and moderate pain at statistically significantly lower temperature
values than did males (p < .05, Cohen’s d = 0.51-0.54). Males, on the other hand, rated
the experience of moderate pain statistically significantly more unpleasant than did the
females (p=.016, Cohen’s d = 0.57).
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Table 3.1: Distribution of MMSE by gender groups.
MMSE1
Cognitively Intact (29-30)
MCI2(25-28)
Mild (20-24)
Moderate (15-19)
Moderately Severe (11-15)
1

2

Female
(n=38)

Male
(n=38)

14
8
9
1
6

17
6
5
6
4

MMSE-Folstein Mini Mental State Examination (range=0-30; 0=completely cognitively
impaired 30=completely cognitively intact).
MCI- mild cognitive impairment.

Associations of MMSE with Psychophysical Reports
Associations of the participant MMSE scores with their psychophysical reports (temperature and unpleasantness) are summarized for the entire sample and by sex in Table 3.4.
A statistically significant inverse association of MMSE with temperature reports at the
warmth threshold was observed for both males and females (r = -0.33 and -0.41 respectively, p < .05) with no statistically significant difference between them (p = .767). Thus,
regardless of sex, temperatures at which a warmth threshold was reported increased as
MMSE scores decreased. Minimal associations were detected between MMSE scores and
temperature reports at either of the other two thresholds for both sex groups (r = -0.13 to
-0.05, p > .50, (Table 3.4).
There was a statistically significant difference between males and females in the
direction of the association of MMSE scores with unpleasantness ratings at the moderate
pain threshold (p = .033). In females, the direction of the association was that ratings of
unpleasantness increased as MMSE scores increased (r = 0.30, p = .072). To the contrary,
in males the direction of the association was reversed; ratings of unpleasantness at that
threshold increased as MMSE scores decreased (r = -0.20, p = .221). Thus, while neither of
the specific correlations within each sex group was statistically significant, the magnitude
of the difference between them in terms of the direction (positive or inverse) was statistically significant (interaction term, p = .033). None of the other associations between MMSE
scores and unpleasantness reports at either of the other two thresholds (warmth or mild
pain) for both sex groups were statistically significant (r = -0.19 to +0.07, p > .20) nor were
any of the tests of difference between those correlations (Table 3.4).
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Table 3.2: Demographic and clinical characteristics of the participants.
Characteristic

Total
(n=76)

Female
(n=38)

Male
(n=38)

P-value

N (%)
Race
White
Age
MMSE1
BPI-average2
BPI Now2
GDS3
STAI State4
STAI Trait4
SES5
1

2
3

4

5

64 (84)

31 (82)
33 (878)
Median [IQR]
73 [68,80] 73 [68,80] 73 [67,81]
28 [20,30] 27 [21,30] 28 [18,30]
0 [0,2]
0 [0,3]
0 [0,2]
0 [0,0]
0 [0,0]
0 [0,0]
1 [0,4]
2 [0,4]
1 [0,3]
48 [44,50] 50 [45,53] 47 [45,50]
47 [44,50] 47 [43,50] 47 [44,49]
54 [41,61] 53 [38,58] 55 [45,62]

.529
.731
.887
.298
.893
.929
.105
.877
.324

MMSE-Folstein Mini Mental State Examination (range=030; 0=completely cognitively impaired 30=completely cognitively intact)
BPI-SF-Brief Pain Inventory Short Form (range=0-10; 0=no
pain, 10=most pain)
GDS-SF-Geriatric Depression Scale Short Form (range; 0=no
indication of depression, 15=high possibility of depression);
Female: n=37, Male: n=37
STAI-Spielberger State or Trait Anxiety Inventory (range;
20=indicates increased anxiety, 80=indicates least amount of
anxiety); Female: n=34, Male: n=32
Hollingshead Four Factor Measure of Socio-Economic Status (range=8-66; 8=lowest SES, 66=highest SES) Female:
n=38, Male: n=36
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Table 3.3: Psychophysics of temperature thresholds necessary to produce
warmth, mild pain, or moderate pain and unpleasantness ratings at each
condition.
Psychophysics

Female
(n=38)

Male
(n=38)

P-value

Cohen’s d

Median[IQR]
Temperature1
Warmth
Mild Pain
Moderate Pain
Unpleasantness2
Warmth
Mild Pain
Moderate pain
1
2

33 [32,35]
35 [35,40]
39 [38,43]

33 [32,36]
39 [35,44]
44 [37,46]

.139
.022
.029

0.34
0.54
0.51

0 [0,1]
3 [0,5]
5 [2,8]

0 [0,2]
4 [1,6]
7 [5,11]

.115
.140
.016

0.30
0.33
0.57

Temperature was measured in degrees Celsius (range = 30–55
°C).
Unpleasantness was measured by numerical descriptor scale (0
= neutral, 20 = extremely unpleasant).
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Table 3.4: Correlations of MMSE scores with temperature and
unpleasantness ratings at each threshold level for the entire sample and
within gender groups.1
Psychophysics

Overall
(n=76)

Female
(n=38)

Male
(n=38)

Difference
p-value2

r (p-value)
Temperature
Warmth
Mild Pain
Moderate Pain
Unpleasantness
Warmth
Mild Pain
Moderate Pain
1

2

-0.36 (0.001)
-0.09 (.460)
-0.08 (.482)

-0.41 (.010)
-0.13 (.442)
-0.05 (.766)

-0.33 (.44)
-0.07 (.671)
-0.11 (.508)

.767
.959
.720

-0.01 (.990)
-0.07 (.543)
0.03 (.772)

-0.04 (.833)
0.07 (.698)
0.30 (0.072)

0.01 (.953)
-0.19 (.249)
-0.20 (.221)

.857
.265
.033

Associations of the participant MMSE scores with their psychophysical
reports (temperature and unpleasantness).Skewed distributions were
transformed to normal for Pearson correlations (r) and linear regressions. Warmth threshold: Both temperature and unpleasantness values
were rank transformed. Mild and moderate pain thresholds: Unpleasantness values were square-root transformed.
Centered sex*MMSE interaction effect after controlling for main effects
of sex and MMSE in linear regression analysis
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Discussion
We found in both males and females that those with a lower global cognition rating required a higher temperature to elicit the perception of pain and males tended to report
greater unpleasantness. This result parallels our previously reported pilot study (Cowan
et al., 2017) from this sample in which males with AD only, reported pain as more unpleasant. This study extends these findings in individuals across the cognitive spectrum. Irrespective of cognitive status in the parent study, males reported pain as more unpleasant.
These results are important because they demonstrate that sex differences in the perception
of pain might be present across the cognitive spectrum.
Our finding that a greater pain stimulus is required to elicit the perception of pain
with worsening cognition agrees with several previous studies from our laboratory and
others (Cole et al., 2006; Kunz, Scharmann, et al., 2007; T. B. Monroe, Carter, et al., 2013;
T. B. Monroe, Gore, Chen, et al., 2012; Scherder, Sergeant, and Swaab, 2003). As mentioned
above, we have previously shown using the same methods described in this paper that
people with a clinical diagnosis of AD demonstrated higher thermal thresholds for the
detection of “warmth,” “mild pain,” and “moderate pain (T. B. Monroe, Gore, Bruehl, et
al., 2015).” Others have found that people with AD demonstrated higher mechanical pressure pain thresholds and increased detection thresholds for electrical shock pain threshold
(Cole et al., 2006; Gibson et al., 2001) respectively. Regarding sex effects on the detection
of thermal pain stimuli unlike previous studies, the current study showed no difference
between males and females in pain stimuli required to elicit the perception of pain. Interestingly, while controlling for covariates, the detection of thermal pain may be driven by
possible depression (based on MMSE screening) in males.
Our results of the affective response to pain were like those reported for younger
adults; males show greater pain-associated unpleasantness than females (Kunz, Scharmann, et al., 2007; Kunz, Mylius, et al., 2009). The current study found evidence to
suggest that in males worsening global cognitive function was associated with higher reports of unpleasantness in the presence of weak and moderate pain. This finding supports Benedetti and colleagues (Benedetti et al., 1999), who reported increased tolerance to
highly unpleasant evoked pain stimuli (electrical shock and ischemic arm pain) in people
with worsening AD.
As an exploratory secondary analysis, there are some obvious limitations in the
current study to consider when interpreting results. The parent study was not powered to
detect sex differences, and the sample size was moderate. Other sensory modalities (e.g.,
somatosensory, auditory) may contribute to the overall pain experience which was not in
the scope of this paper. As we have previously noted (T. B. Monroe, Gibson, et al., 2016),
a perceptual matching paradigm was used rather than a fixed temperature for thermal
sensory detection levels. This procedure may have impacted the pattern of findings for
pain unpleasantness in unknown ways. To comply with IRB recommendation, we used
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the Method of Limits program on the Medoc Pathways Model so that the individual (regardless of cognition) was in control of the perceptual pain stopping point.
For this reason, we were unable to collect any perception above the rating of “moderate pain,” specifically avoiding the perception of “severe pain” or the perception of “pain
tolerance.” This design was developed based on the mechanical pressure paradigm used
by Cole and colleagues (Cole et al., 2006) in their perceptual matching paradigm of people
with AD. Despite these limitations, the current study adds to the limited number of clinical and experimental pain studies examining sex-differences in altered pain response in
people with cognitive impairment. Another strength of the design is that the authorship
team includes authors with experience in the legal and ethical issues in pain research in
people with cognitive impairment (T. B. Monroe, Herr, et al., 2013).
The clinical relevance of these findings suggests that, in either sex, the diminished
ability to detect pain could lead to an increase in adverse outcomes, such as an increase in
the length of hospitalization (Morrison et al., 2003). Additionally, the increased reporting
of unpleasantness in males may increase the risk of suffering from pain in those with worsening cognition. Relative to cognitively healthy controls, people with worsening cognition
generally have an altered response to clinical and experimental pain. Sex differences in
pain reports compound the risk of increased pain in those with worsening cognition, especially when one-dimensional pain intensity scales are used that do not measure pain
affect.
In summary, the current study found that sex-differences in pain experiences may
be present in older adults with varying degrees of cognition. Future studies are needed to
replicate these results and should include an examination of the response to fixed temperatures and neurophysiological basis of sex differences in pain processing in a wide range
of ages and across the spectrum of cognitive functioning. In consideration of mounting
evidence, we continue to advocate that clinicians consider using a multi-dimensional sensory and unpleasantness pain tool in clinical practice as males and females may ultimately
report pain intensity and pain unpleasantness differently, regardless of cognition. Using
pain intensity measures only may predispose to suffering by not capturing an essential
dimension of pain.
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Chapter 4
Sensory Changes as a Biomarker for Alzheimer’s
Disease1

Background
In the most recent publication of the “Alzheimer’s Disease Facts and Figures” the Alzheimer’s Association presented evidence suggesting a potential of savings of $7 trillion dollars resulting from the early diagnosis of Alzheimer’s disease (AD), a point at which 70%
of those with AD are diagnosed in the prodromal phase of the illness or prior to the development of observable signs or symptoms of AD (“2019 Alzheimer’s disease facts and
figures” 2019). One current challenge is the lack of robustness in methods that detect AD,
particularly in the very early stages of the disease. Early subtle changes in memory and
cognition occur over the course of months to years making it difficult to recognize symptoms in patients, and often health care providers wrongly misattribute small changes in
cognitive function as a process of normal aging (Knopman, Donohue, and Gutterman,
2000). Evidence of a complex pathophysiological process of AD is accumulating that indicates pathological change is detectable years before, rather than at the beginning of, the
prodromal phase as neuropathologic examinations of adults clinically diagnosed without
cognitive impairment reveal similar pathological signatures to those with AD (Dubois,
Feldman, et al., 2007).
Recently, The National Institute on Aging (NIA) published a framework for the
diagnosis of AD that shifted the understanding of AD as a syndrome or the clinical consequence of one or more diseases towards a biological process that incorporates measurable
physiological parameters or biomarkers (Jack et al., 2018). Current biomarkers of AD are
grouped into those of β amyloid deposition (A), pathologic tau (T), and neurodegeneration (N) and are typically gathered by advanced imaging and lumbar puncture (Jack et al.,
1 Reprinted

from the final submission with permission. Romano R.R., 3rd, M. A. Carter, and T. B. Monroe (2020). “Narrative Review of Sensory Changes as a Biomarker for Alzheimer’s Disease”. In:Biol Res
Nurs,p. 1099800420947176. ISSN: 1552-4175 (Electronic) 1099-8004 (Linking)DOI:10.1177/1099800420947176.
URL:http://www.ncbi.nlm.nih.gov/pubmed/32799655.
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2018). In the primary care setting it is difficult to detect pre-clinical AD because detection
methods using imaging, invasive CSF test, and biomarker testing are rarely available outside of specialty clinics (Mortamais et al., 2017). Health care providers are advised to focus
on the core criteria for diagnosis of clinical AD, which do not require biomarker evidence,
but rely on clinical evaluation and neuropsychological testing (Tolea and Galvin, 2013).
Since there is variation in the diagnostic abilities of primary care providers, research has
focused on finding non-invasive biomarkers that may be helpful to health care providers
in identifying AD (3. Romano R. R., Carter, Anderson, et al., 2020).
Alterations in sensations may be a useful biomarker. Senses are multisystem physiological mechanisms of perception traditionally categorized as smell, taste, sight, hearing,
and touch, but also include the ability of humans to sense temperature (thermoception),
body position (proprioception), pain (nociception), balance (equilibrioception), and touch,
thirst and hunger (mechanoception) (Matlin and Foley, 1992). Stimuli interact with sensory
receptors that initiate action potentials processed in the central nervous system to elicit an
action (Matlin and Foley, 1992). In early AD, pathological changes in the brain may result in alteration in sensory perception and provide insight that may be helpful to identify
those at risk for AD. This paper aims to explore what is known about current biomarkers
using a focused and limited narrative review of the scientific literature pertaining to sensory changes as potential biomarkers for AD. Whittemore and Knafl, 2005 contend that a
narrative review is the preferred method of organizing a body of literature, as this type of
review allows for a combination of diverse methods to provide an in-depth understanding
of a phenomena of interest and deepen understanding. The question posed for this review
was “What is the current understanding of alterations in senses as potential biomarkers
for AD?”

Methods
An analysis of the existing literature was undertaken to meet the study aim. Empirical studies published in English were included in this analysis. These included studies that examined traditional senses (sight, hearing, taste, smell, and touch); the detection of other stimuli (thermoception, proprioception, nociception, equilibrioception, and
mechanoreception); and response to internal stimuli (hunger and thirst) that used multiple senses. Further, to be considered eligible, the sense had to be investigated in the study
as a biomarker defined as a measurable and quantifiable biological parameter that can be
used as an index for dementia. Data items extracted from the literature included method
of sensation-testing, measure of clinical disease, and association with diagnosis.
A search of English-language studies reporting associations between alterations in
sensory modalities and diagnosis of dementia was conducted using 3 databases: PubMed
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(May 2020), CINAHL (May 2020), and PsycINFO (May 2020). Search terms included “sensation,” “dementia,” “Alzheimer’s disease,” and “biomarker” as well as each sense individually (i.e., sight, hearing, taste, smell, touch, thermoception, proprioception, nociception, equilibrioception, and mechanoreception). All potential studies identified by this
search (N = 78) were exported directly to EndNote and reviewed for eligibility after duplicated studies were removed.
Articles were excluded if not topically related based on title and subsequent reading of the abstract to assure that a sense was investigated as a biomarker, defined as a
measurable and quantifiable biological parameter used as an index for Alzheimer’s disease. Further, articles identified as literature reviews, editorials, or commentaries were
excluded, and manuscripts without readily available full texts were removed from the
sample (see Figure 4.1). Studies were organized according to sensory systems. Data were
extracted independently by the first author (RR) using a piloted data collection form, and
any ambiguous information was settled by consensus among all authors. The quality of the
studies was assessed using the study design-specific (e.g., observational cohort or crosssectional studies quality assessment tool) tool developed by the National Heart, Lung, and
Blood Institute (NHLBI) and Research Triangle Institute International (Study Quality Assessment Tools, 2020). We awarded point values (e.g., No = 0, Yes =1, Good = 2, Fair = 1,
Poor = 0) to each assessment of quality and totaled them for the final score quality score so
that the higher the total score the better the quality.

Results
A total of 78 manuscripts were identified in the initial sample. The final literature review
sample consisted of 18 studies after removing 3 duplicate manuscripts, 28 topically unrelated (e.g., ligand correlations to disease state, behavioral paradigms, depression related
studies) or methodologically unacceptable manuscripts (e.g., reviews, commentaries, and
editorials), 26 non-empirical manuscripts, and 3 non-human studies. The olfactory system
was investigated in 12 manuscripts and was the most represented sense in the final sample.
The other sensory systems in the final sample included auditory, vision, proprioception,
and taste (Figure 4.1). No other sensory system studies were identified by this search.

Olfactory
Olfaction has been proposed as a biomarker for AD since Esiri and G. K. Wilcock, 1984
compared the olfactory bulbs in AD patients and normal controls and found that patients
with AD had collections of neurofibrillary tangles in the anterior olfactory nucleus. There
were 12 manuscripts reviewed concerning the olfactory sense as a biomarker for AD. All
manuscripts were cross-sectional analyses, with 1 manuscript published in 1996 by Serby
et al., 1996 having a 5-year follow-up (Table 4.1).

Chapter 4. Sensory Changes as a Biomarker for Alzheimer’s Disease

Figure 4.1: Consort prisma flow diagram.

31

Chapter 4. Sensory Changes as a Biomarker for Alzheimer’s Disease

32

Table 4.1: Description of sample of 12 studies on olfaction as a
biomarker.
Assessment of
Sensation2

Assessment of
Cognition3

Quality
Score

UPSIT

MMSE, ADAS

8

CC-SIT

CAMCOG-C, MMSE

10

Butanol odor
odor discrimination
odor identification

MMSE, CDR

10

SOIT

MMSE, Vocabulary

11

OSIT-J

MMSE, ADAS-cog

9

Cross-sectional
multi group comparison

UPSIT

X

10

Cross-sectional
1-group analysis

UPSIT

MMSE, BNT-30, AmNART

10

4-group
cross-sectional analysis

OPID, POEM, OAS

CDR, MMSE, BNT, TrailsB

9

Author (Year)

Sample Size1

Study Design

Serby et al., 1996

N=28 FDR
N=28 controls

Wang et al., 2002

N=28 MCI
N=30 controls

Peters et al., 2003

N=14 AD
N=8 MCI
N=8 controls

Olofsson
(2010)

N=1236

Jimbo et al., 2011

N=109 AD
N=40 controls

Cross-sectional
2-group comparison
Cross-sectional
2-group
age-matched comparison
Cross-sectional
3-group
age-matched comparison
5-year longitudinal
cohort study
Cross-sectional
2-group
age-matched comparison

Masaoka et al., 2013

N=16 AD
N= PD
N= DM1
N=67 controls

Growdon et al., 2015

N=215 CN

Dhilla Albers et al., 2016
Lafaille-Magnan et al., 2017
Quarmley et al., 2017
Tonacci et al., 2017
Kouzuki et al., 2018
1
2

3

N=10 AD
N=29 MCI
N=74 SCC
N=70 controls
N=274
N=262 AD
N=174 MCI
N=292 controls
N=85 MCI
N=41 controls
N=40 AD
N=34 MCI
N=40 controls

Cross-sectional

UPSIT

RBANS, MoCA

11

Cross-sectional
3-group comparison

SS-OIT

MoCA

11

Cross-sectional
age and gender-matched

OTT, ODT, OIT

Free DCT, RAVLT, ROCF, BSS,
MMSE, CDR, ADL, ADAS-cog

9

Cross-sectional analysis

OSIT-J

MMSE, ADAS-J, TDAS

10

Abbreviations: FDR (First-degree relatives), MCI (Mild cognitive impairment), AD (Alzheimer’s disease), PD (Parkinson Disease), DM1
(Diabetes Mellitus Type 1) SCC (Subjective Cognitive Concerns)
Abbreviations: UPSIT (University of Pennsylvania Smell Identification Test), CC-SIT(Cross-Cultural Smell Identification Test), SOIT (Scandinavian Odor IdentificationTest), OSIT-J (Odor Stick Identification Test for the Japanese), OPID (Odor PerceptIDentification), POEM (Perception of Odor Episodic Memory), OAS (Odor AwarenessScale), SS-OIT (Sniffin Sticks Odor Identification Test), OTT (Odor Threshold
Testing,ODT (Odor Detection Threshold), OIT (Odor Identification Test).
Abbreviations: MMSE (Mini Mental State Exam), ADAS (Alzheimer’s Disease Assessment Scale), CAMCOG-C (Cambridge Cognitive
Examination Chinese version), CDR (Clinical Dementia Rating), Vocabulary (Cureman and Salde, 1959), ADAS-cog (Alzheimer’s Disease Assessment Scale-cognitive subscale), BNT (Boston Naming Test, AmNART (American National Adult Reading Test), TrailsB (Trails
Making Test B), RBANS (Repeatable Battery for the Assessment of Neuropsychological Status), Free DCT (Dot Counting Test), RAVLT (Rey
Auditory Verbal Learning Test), ROCF (Rey–Osterrieth complex figure test), BSS (Bhatia Battery of Performance tests of Intelligence), TDAS
(Touch Panel-type Dementia Assessment Scale)
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The sample size of studies ranged from n = 30 to n = 728 and compared participants
with AD to those with mild cognitive impairment, frontotemporal dementia, or healthy
controls. Five studies were conducted in the United States, while the remaining studies
were conducted in Japan (n = 2), Canada (n = 1), Sweden (n = 1), Italy (n = 1), Germany (n
= 1), and China (n = 1). The quality of the manuscripts reviewed ranged from a score of
8-11, suggesting high-quality design and analysis.
Serby et al., 1996 found that first-degree relatives performed worse on a measure
of odor identification when compared to a control group of community-dwelling older
adults; further, the authors argued that impaired olfaction may be present before clinical
symptoms. Similarly, 2 studies of participants with mild cognitive impairment (MCI), a
known risk factor for AD, showed odor identification was impaired in people with MCI
when compared to age- and gender-matched, cognitively normal controls, further adding
to the evidence that suggests changes in the olfactory system may be useful in identifying
those at risk for AD (Peters et al., 2003; Tonacci et al., 2017). These subsequent studies
used similar methods to Serby et al., 1996. The manuscripts in the sample all found significant associations with measures of olfaction and AD diagnosis (Quarmley et al., 2017).
Two studies that specifically evaluated APOE4 status found significant associations with
deficits in odor identification (Lafaille-Magnan et al., 2017; Wang et al., 2002). Most studies found olfactory function decreased in AD and MCI patients and was associated with
either cerebral spinal fluid biomarker levels (Kouzuki et al., 2018; Lafaille-Magnan et al.,
2017), genetic status (Lafaille-Magnan et al., 2017; Wang et al., 2002; Olofsson et al., 2010,
worse performance on measures of cognitive function (Dhilla Albers et al., 2016; Jimbo et
al., 2011; Lafaille-Magnan et al., 2017; Masaoka et al., 2013; Peters et al., 2003), or changes
in brain structure as observed through imaging modalities (Growdon et al., 2015).
Though olfaction has been the most common sense evaluated as a potential biomarker for AD, challenges may occur when using olfaction as a screening process in primary
care because assuring reliability and specificity can be problematic since conditions such
as seasonal allergies can yield confusing results. Cultural exposure to certain scents may
vary and make it difficult to find a generalizable test. Offensive scents may also stimulate
the trigeminal nerve rather than the olfactory nerve, further complicating the reliability of
screening.

Taste
Taste and smell are closely related, as both senses converge in the caudal orbitofrontal
cortex, yet research has mostly focused on the association between smell and AD. Neuroimaging techniques are able to visualize taste perception in cerebral representations and
suggest that gustatory processing may be impaired in people with brain disease (Camicioli
et al., 1998; Lang et al., 2006). Naudin et al., 2015 conducted a cross-sectional analysis and
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found that people with AD gave significantly more incorrect responses on salty, bitter, and
sweet taste identification tasks when compared to healthy controls.

Auditory
The next most common sensory system reported as a potential biomarker has been hearing. The quality of the 2 studies included in this review can be considered strong, with
scores of 10 on the design-specific quality assessment tool. Waldton, 1974 first showed
functional impairment of the cranial nerves in 66 women with senile dementia. Further hearing loss becomes more prevalent as people age, making it a notable sense to
study in the AD population. Autopsy studies have confirmed hallmarks of AD pathology,
Aβplagues, and tau were identified in the cochlear nucleus and throughout the auditory
system in patients with AD. Of the auditory manuscripts reviewed, found positive associations with changes in auditory response and either markers of AD (total-tau and p-tau) or
measures of cognition (Laptinskaya et al., 2018; Tuwaig et al., 2017). The first study, published by Tuwaig et al., 2017, was a 2017 cross-sectional analysis of 187 cognitively normal,
high-risk members of the PREVENT-AD cohort that found 2 tests of auditory abilities were
associated with measures of cognition, concentration of total-tau and p-tau, measures of
hippocampal and entorhinal cortical volumes, and cortical thickness. However, the authors did not find an association between the measures of central auditory processing and
APOE4 carrier status.
The second auditory study reported significant changes in the event-related response in an EEG signal caused by alteration of auditory stimulation after a long interstimulus interval, and this change in EEG signal was associated with worse episodic memory
performance at five-year follow-up (Laptinskaya et al., 2018). Although limited, there is
growing evidence of hearing loss as a potential indicator of AD; however, it is unclear
if these changes are associated with AD pathology or with temporal lobe abnormalities
related to aging (Murphy, 2019).

Vision
Changes in vision has been identified as another possible marker of AD, given that amyloidbeta plagues have been identified in the aqueous humorous of AD patients undergoing
cataract surgery. In 2013, Risacher and colleagues accurately identified people with MCI
relative to healthy controls using vision testing (Risacher, Wudunn, et al., 2013). The authors also determined that people with AD and MCI demonstrated significant contrast
sensitivity visual deficits, which also is associated with worse performance of cognitive
measures.
In a later cross-sectional analysis, Balachandar and colleagues (2017) found that
people with mild AD exhibited significant associations between deficits on visuospatial
measures and changes in resting-state functional connectivity (Balachandar et al., 2017).
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Vision changes may prove to be an inadequate biomarker, as there remains discussion on
the timing of vision pathology and AD clinical disease as well as the fact that alteration in
vision is a part of healthy aging in addition to part of other confounding disease processes
(Murphy, 2019).

Proprioception
Proprioception, or the awareness and perception of one’s body in space, has the potential
to be an early marker of AD pathology, as motor decline is observed in all stages of AD
(Boyle et al., 2007). A slowing of walking speed that proceeds cognitive decline was first
observed 2 decades ago and is explained by the overlap in the brain structures (i. e., the
cerebellum, basal ganglia, and motor cortex) responsible for walking and involved in attentional, executive, and visuospatial functions (Camicioli et al., 1998). Tu and colleagues
(2015) used a virtual supermarket task to discriminate between participants with AD and
frontotemporal dementia (Tu et al., 2015). The authors found that people with AD had
more impairment in orientation compared to people with FTD and concluded that orientation had the same level of diagnostic sensitivity as other measures of episodic memory
(Tu et al., 2015). This evidence supports the use of tests of proprioception as a tool to
identify persons with AD.

Discussion
The current state of the literature shows a paucity of research in how non-traditional senses
may be used as biomarkers for AD. Yet, the results do suggest further research is warranted
as the majority of studies reviewed demonstrate that sense perception changes at different
diagnosis categories (e.g., AD, MCI, normal). Results from this review are promising as
they suggest that future research in this area could shed light on other methods of assessment that may be more feasible and less invasive than current practice recommendations
such as lumbar puncture, MRI, and PET scans to identify those with Alzheimer’s disease.
Overall, olfaction was the most widely studied sense. Researchers of the 12 manuscripts
reviewed showed measures of olfaction were associated with changes in cognition, imaging, and APOE status. Though limited in scope, this review demonstrates how a lack of
evidence supporting how other senses could be used as a biomarker for AD serves as a
clear gap in the literature. Evidence from all manuscripts included in the current review
indicates deficits or changes in senses can potentially be used to differentiate between people with AD, MCI, and cognitively normal adults.
One possible, yet under studied area for AD biomarkers is pain. AD is well-known
to cause changes in brain structures and metabolism (T. B. Monroe, Beach, et al., 2017; T. B.
Monroe, Fillingim, et al., 2018). The hippocampus and prefrontal cortex experience the
most brain volume loss with healthy aging; however, in individuals with AD, the entorhinal cortex and hippocampus and the lateral temporal lobe and neocortex have significantly
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more volume loss compared to healthy individuals (T. B. Monroe, Gore, Chen, et al., 2012).
As AD progresses, damage typically occurs in both the lateral and medial pain network.
Studies have shown that neurofibrillary tangles and β amyloid plaques accumulate in the
amygdala (Kromer Vogt et al., 1990), orbitofrontal cortex (Tekin et al., 2001), insula, PAG
(Parvizi, Van Hoesen, and Damasio, 2000), and striatum (Selden et al., 1994), all of which
comprise the rostral pain system (T. B. Monroe, Gore, Chen, et al., 2012). People with AD
have alterations in pain perceptions, and this has been shown to be different when compared to cognitively normal adults (T. B. Monroe, Gibson, et al., 2016; T. B. Monroe, Gore,
Bruehl, et al., 2015; R. R. Romano et al., 2019). Measuring pain perception in individuals
who are very early in the process of AD is not complex and could be adapted to most
primary care practices. Also important is that the association between changes in pain
perception in AD is theoretically sound (T. B. Monroe, Gore, Chen, et al., 2012). Pain is not
a single sense per se, as multiple areas of the brain are used in pain perception, and this
complexity may allow alterations in pain perception to be used as an early biomarker for
AD.

Implications for Research
New therapeutic agents are being explored that hold promise for clinicians to be able to offer treatment that alters the progression of AD (Cummings et al., 2019). However, the state
of the science in identifying non-invasive biomarkers for AD that can be identified prior
to the onset of cognitive impairment is still in the early stages. The results of this review
suggest that additional focus should be directed on alternation of senses as a potentially
useful biomarker. Further the results of this review identify a clear gap in the literature
as only one nontraditional sense manuscript was identified through this review. If senses
prove to be useful noninvasive biomarkers then clinicians might have feasible, simple,
and non-invasive methods available to identify people who have early or asymptomatic
AD for early treatment.

Limitations
Narrative reviews have a number of potential limitations. Defined parameters and boundaries can pose a challenge. In this study, the selection of the search terms was believed to
be appropriate, but there is a possibility that some work may have been missed, as this is
a rarely explored field of scientific work. Every effort was made to assure that the widest
search of the actual research literature was conducted, but the language and/or MeSH
terms may still be ambiguous. Further, the majority of data collection was conducted by
the primary author; however, the final sample of manuscripts were reviewed by all authors and any disagreement on interpretation of the results (Table 4.2) were discussed and
interpreted by group consensus.
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Table 4.2: Quality scores of auditory, vision, proprioception, and taste
studies.
Author (Year)
Laptinskaya (2018)
Tuwaig (2017)
Balachandar (2017)
Risacher (2013)
Tu (2015)
Naudin (2015)
1

Quality Score1
10
10
9
9
9
10

Study Quality Assessment Tools.
(2020).
National Heart, Lung,
and Blood Institute.
Retrieved
July 13 2020 from https://www.
nhlbi.nih.gov/health-topics/
study-quality-assessment-tools
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Chapter 5
Could an Altered Evoked Pain Response Be a
Phenotypic Biomarker for Alzheimer’s Disease Risk?1

Background
Earlier diagnosis of Alzheimer’s disease (AD) has been shown to reduce cost and improve patient outcomes despite the limited availability of current treatment options (“2020
Alzheimer’s disease facts and figures” 2020). One method used to initiate earlier diagnosis
is identifying AD prior to the onset of classical signs or symptoms, and biomarkers hold
potential of serving this function. Currently recognized biomarkers of AD are invasive and
not practical in the primary care setting where the majority of patients with memory concerns first seek care (“2020 Alzheimer’s disease facts and figures” 2020; Wilkinson et al.,
2004. An initial report of increased neurofibrillary tangles in olfactory bulb in people with
AD spurred further studies directly investigating sensory processing in AD. (Esiri and
G. K. Wilcock, 1984). Since that early report, studies have demonstrated that changes in olfaction, taste, hearing, vision, and proprioception have the potential to serve as biomarkers
of AD (3. Romano R. R., Carter, and T. B. Monroe, 2020).
Current approaches used to identify individuals with AD include lumbar puncture
with analysis of cerebral spinal fluid, magnetic resonance imaging, and positron emission
tomography scans (“2020 Alzheimer’s disease facts and figures” 2020). These approaches
are invasive, costly, and not widely available or feasible in the primary care setting(Iliffe,
Robinson, et al., 2009). In contrast, measures of sensory changes are less invasive, more feasible, and readily available in primary care practices where most individuals present for
initial diagnosis (Wilkinson et al., 2004; 3. Romano R. R., Carter, and T. B. Monroe, 2020).
Sensory processing for all senses (e.g., olfaction, vision, proprioception) involves multisystem physiological mechanisms in which stimuli activate sensory receptors, thereby initiating action potentials leading to central nervous system (CNS) processing and ultimately a
1 Romano R. R., 3rd, M. A. Carter, M. S. Dietrich, R. L. Cowan, S. P. Bruehl and T. B. Monroe. "Could Altered
Evoked Pain Responsiveness Be a Phenotypic Biomarker for Alzheimer’s Disease Risk?: A Cross-Sectional
Analysis of Cognitively Healthy Individuals." Journal of Alzheimer’s Disease. In press.
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perceptual response(Matlin and Foley, 1992).AD-related changes in the CNS have the potential to alter all such sensory processing (3. Romano R. R., Carter, and T. B. Monroe, 2020).
Processing of pain stimuli in the CNS occurs in the lateral (sensory) and medial (emotional)
brain networks with the integration of the rostral (behavioral) network in healthy individuals and at varying degrees of neurocognitive impairment, people may present with increased or decreased pain-related behaviors coupled with increased or decreased reports
of pain intensity and pain unpleaseantness (T. B. Monroe, Gore, Chen, et al., 2012). Several studies have demonstrated that the perception of controlled experimentally-induced
pain stimuli differs between cognitively healthy people and people with AD (T. B. Monroe, Gore, Chen, et al., 2012; T. B. Monroe, Beach, et al., 2017; T. B. Monroe, Fillingim, et al.,
2018; T. B. Monroe, Gibson, et al., 2016; R. R. Romano et al., 2019, which suggests that
pain processing is altered in the AD. However, changes in pain processing have not been
directly linked to genetic markers for AD. Thus to date, the phenotypic association of the
ε4 allele has not been considered in pain outcomes.
The ε4 allele of apolipoprotein E (APOE) is a genetic marker associated with an
increased incidence of developing late-onset AD and is a risk factor identifiable long before
the onset of AD symptoms (Najm, E. A. Jones, and Huang, 2019; Safieh, Korczyn, and
Michaelson, 2019; Yamazaki et al., 2019). The APOE gene encodes the production of a
299 amino acid ligand that is primarily synthesized in astrocytes of glial cells in the brain,
the liver, and macrophages in peripheral tissue and is mostly responsible for transporting
cholesterol (Najm, E. A. Jones, and Huang, 2019; Safieh, Korczyn, and Michaelson, 2019;
Yamazaki et al., 2019; Maehlen et al., 2013). APOE can take on three isoforms dictated
by three polymorphic alleles—ε2, ε3, and ε4—resulting from a difference in only one or
two amino acids (Safieh, Korczyn, and Michaelson, 2019; Yamazaki et al., 2019). The most
common allele, APOE ε3, is present in 50-90% of all populations; APOE ε4 is distributed
in about 5-35%; and APOE ε2, the least common allele, is distrubted in about 1-5% of the
population (Mahley and Rall, 2000; Verghese, Castellano, and Holtzman, 2011; Ward et
al., 2012). Genetically, a person can be homozygous (i.e., ε4/ε4, ε3/ε3, and ε2/ε2) for one
major subtype or heterozygous (ε4/ε3, ε3/ε2, and ε4/ε2) for two main subtypes, resulting
in six different phenotypic populations (Yamazaki et al., 2019). The risk of developing
AD changes between genetic profiles, as those with the greatest odds of developing AD
include ε2/ε4, ε3/ε4, and ε4/ε4, while those with reduced odds include ε2/ε2 and ε2/ε3
(Najm, E. A. Jones, and Huang, 2019; Yamazaki et al., 2019; Maehlen et al., 2013). A recent
meta analysis of AD populations estimated about 49% as being APOE ε4 carriers and about
10% as ε4/ε4 positive carriers and noted that carrying at least one copy of the ε4 allele
increases risk 3-fold when compared to healthy controls and almost 12-fold for those with
two ε4 alleles and When compared to ε3 carriers, APOE ε4 positive individuals have three
times the risk of developing AD (Ward et al., 2012).
The aim of the current study was to determine whether individuals at increased risk
of late-onset AD based on APOE allele genotype differ phenotypically in their response to
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experimentally-induced painful stimuli compared to those who do not have at least one
copy of ε4 allele.

Methods
Study Participants
Recruitment, enrollment, psychophysical testing, and cognitive assessments techniques
are previously described (T. B. Monroe, Beach, et al., 2017). English-speaking, verbally
communicative participants aged 30-89 years were recruited between 2014 and 2017 from a
Mid-south metropolitan area. Participants were excluded for the presence of chronic pain;
cognitive impairment (Mini-Mental State Exam [MMSE] < 28) (M. F. Folstein, S. E. Folstein,
and McHugh, 1975); daily use of analgesic medication; or history of stroke, cancer, peripheral neuropathy, Raynaud’s Disease, unstable medical conditions (e.g., severe restrictive
or obstructive lung disease), insulin-dependent diabetes, current substance use disorders,
or psychiatric diagnoses of bipolar disorder, major depressive disorder, schizophrenia; or
presence of movement disorders including Parkinson’s disease and restless leg syndrome.
The Vanderbilt University Institutional Review Board approved the study. All participants
were compensated US $100 for their time.

Screening and Enrollment
Eligibility was assessed using a two-part screening process via telephone or in-person visit.
Participants underwent one hour of psychosocial assessment, including medication use,
demographic information, Hollingshead Four-Factor SES (Hollingshead, 1975) and cognitive screening with the MMSE (M. F. Folstein, S. E. Folstein, and McHugh, 1975). Participants were assessed with the Brief Pain Inventory (BPI) (Cleeland and Ryan, 1994), 5-item
World Health Organization Well-Being Index (Hamilton, 1960), and State-Trait Anxiety
Inventory (STAI) (Spielberger, 1971).

Thermal Stimulation Protocol (Psychophysics)
The thermal stimulation protocol used in the study assessed two aspects of pain: the intensity of pain and the unpleasantness of pain. The protocol was a modification of the
perceptual matching experimental mechanical pressure pain protocol used by Cole and
colleagues (Cole et al., 2006) and used the Medoc Q-Sense™. This device evokes simulation of A-delta and C-fibers (Hunt and Koltzenburg, 2005; Wager et al., 2004). The Medoc
thermode (30×30 mm) was attached to the thenar eminence of the right hand of each participant, and participants were shown a 0–20 sensory pain intensity scale and asked to stop
the heat stimulus (via clicking a computer mouse) when they felt “just noticeable pain,”
“weak pain,” or “moderate pain” (with each precept tested in separate trials). Participants
were then asked to rate the unpleasantness of the sensation at each pain intensity percept
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using a 0–20 unpleasantness scale with the following anchors: “0=neutral,” “5=slightly
unpleasant,” “8=unpleasant,” “11=very unpleasant,” “16=intolerable,” and “20=extremely
distressing”(Petzke et al., 2005).
The baseline temperature was set as 30°C (a temperature not perceived as warm
or cold), and the thermode was programmed to deliver heat that increased at a rate of
4°C/second. We modeled our thermal stimulus delivery after Wager and colleagues’
paradigm in which each temperature stimulus began from baseline and ramped up and
down at a moderate rate (Wager et al., 2004). Subsequently, we recorded the temperature
at which each participant reported the perceptions of just noticeable pain (indicator of pain
threshold), weak pain, and moderate pain. Each participant completed three pseudorandomized trials consisting of two instances at each percept level. The average temperature
(°C ) across the trials at each level of intensity was used in analyses (maximum temperature=50°C). Immediately after indicating the first stimulus meeting criteria for each of the
three intensity levels, participants were asked to rate the unpleasantness associated with
that stimulus level as described above. Ten seconds of rest was provided between each
percept in each trial.

APOE4 Status Determination
Participants supplied 2 mL of saliva which was collected and stored in an OrageneTM
saliva collection tube. APOE genotype was determined using TaqManTM assays. For statistical analysis, participants were categorized as either being APOE4 positive (APOE ε3/ε4,
ε4/ε4) or APOE4 negative (APOE ε2/ε2, ε2/ε3, ε3/ε3).

Statistical Analysis
Frequency distributions were used to summarize nominal and ordinal data. Due to the
skewness of many of the continuous distributions, median and inter-quartile range were
used to summarize the continuously scaled measures. Mixed-effects (between-subject:
APOE4 allele status; within-subject: three percept levels) general linear models tested the
main and interaction effect of allele status (negative, positive) and percept level (warmth,
mild pain, moderate pain) on the temperature at which each level was reported and on
the unpleasantness value of the pain at that level. Pairwise Mann-Whitney U tests were
used to assess pairwise differences at each percept level. Distributions were square root
transformed to meet the normal assumptions of the models used and to calculate Cohen’s
d effect size statistics for the group differences at each threshold level. An alpha level of
p<0.05, set a priori, was used for statistical significance determinations.
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Figure 5.1: Consort flow diagram.

Results
Sample Characteristics
A total of 92 participants were screened; 32 participants were excluded prior to enrollment
for not meeting inclusion criteria; 60 participants were enrolled; of those, 1 participant
was lost to follow-up, 7 participants were excluded for failure to provide sufficient salvia
volume for genetic analysis, and 3 participants had incomplete data leaving a final sample
of 49 (Figure 5.1).The majority of participants carried the ε3/ε3 alleles (n=27, 55%), and
the remaining allele distributions were ε3/ε4 (n=10, 20%), ε2/ε3 (n=8, 16%), ε2/ε2 (n=2,
4%), and ε4/ε4 (n=2, 4%). There were no participants with ε2/ε4 alleles. Slightly more
than half the sample was male (n=26, 53%) and a majority were white (n=38, 78%). Sample
characteristics are summarized in Table 5.1. Median age of the sample was 68.0 years (IQR:
48-80 and median MMSE score was 30.0 (IQR: 29-30). There were no statistically significant
differences between APOE4 positive (n=12) and APOE4 negative (n=37) participants on
any of the characteristics investigated including average pain and current pain scores on
the BPI (p > .05, Table 5.1).
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Table 5.1: Demographic and sample characteristics.

Psychophysics

Age
SES1
MMSE2
BPI-SF average pain3
BPI-SF pain right now3
WHO-54
STAI state Y form5
STAI trait6
1
2
3
4
5
6

APOE4 Negative
(n=37)
68.0 (48-80)
52.5 (49-58)
30.0 (29-30)
0 (0-0)
0 (0-0)
19.0 (17-21)
15.0 (15-16)
47.0 (45-49)

APOE4 Positive
(n=12)
Median (IQR)
49.0 (33-80)
58.0 (51-88)
30 (29-30)
0 (0-0)
0 (0-0)
19.5 (16-21)
15.0 (14-15)
46.5 (44-49)

Total
(n=49)

P-value

65.0 (46-80)
53.5 (49-60)
30 (29-30)
0 (0-0)
0 (0-0)
19.0 (17-21)
15.0 (15-15)
47.0 (44-49)

.192
.131
.339
.783
.817
.699
.544
.565

Hollingshead Four-Factor Measure of Socioeconomic Status (range=8–66; 8=lowest
SES, 66=highest SES); N=40, Negative=31, Positive=9
MMSE-Folstein Mini-Mental State Examination (range = 0–30; 0 = completely cognitively impaired, 30=completely cognitively healthy)
BPI-SF-Brief Pain Inventory Short Form (range=0–10; 0=no pain, 10=most pain); Current Pain N=48, Negative=37, Positive=11
WHO-5 Well-Being Index (range=0-25, 25=maximal well-being)
STAI-Spielberger State Anxiety Inventory-STATE Y form (range 6-24; 6=increased
anxiety, 24=least amount of anxiety)
STAI-Spielberger Trait Anxiety Inventory (range=20-80; 20=increased anxiety,
80=least amount of anxiety); N=48, Negative=36, Positive=12
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Table 5.2: Experience of pain between APOE4 negative and positive
participants.

Psychophysics
Temperature
Overall
Just noticeable
warmth
Weak pain
Moderate pain
Unpleasantness
Overall
Just noticeable
warmth
Weak pain
Moderate pain
1

APOE4 Negative
(n=37)

APOE4 Positive
(n=12)

p-value1 Cohen’s d

Median °C (IQR)
40.0 (35-45)
42.0 (35-48)

.040

34.0 (32-37)

34.1 (32-36)

.806

0.16

41.0 (37-43)
45.3 (43-48)

42.5 (39-46)
47.9 (45-49)

.139
.057

0.54
0.59

Median (IQR)
4.0 (0-7)
5.5 (1-10)

.014

0.0 (0-1)

0.2 (0-2)

.395

0.23

4.0 (1-6)
8.0 (6-10)

5.8 (4-8)
10.0 (8-13)

.060
.080

0.52
0.50

p-values are for Mann-Whitney tests at each pain threshold level. Values
were square-root transformed to meet normal distribution assumptions of
Cohen’s d.

APOE and Pain
The psychophysical data for APOE4 positive and APOE4 negative participants are summarized in Table 5.2.
Statistically significant main effects of increasing percept intensity were observed
on both stimulus temperature and unpleasantness (p < .001). Thus, as expected, stimulus temperature and unpleasantness both increased as the targeted percept intensity increased from just noticeable to moderate pain. Our primary focus was on the main effects
of APOE4 status. Statistically significant main effects of APOE4 status were noted for the
temperature necessary to elicit the three targeted pain percepts (p=.040) and on the experience of unpleasantness of that pain (p=.014). The APOE4 positive participants were
less pain sensitive overall, that is, they reported reaching the targeted pain percepts at
a significantly higher temperature than did those who were APOE4 negative. However,
when those pain percepts were reached, APOE4 positive participants reported that pain to
be more unpleasant relative to APOE4 negative participants. As shown in Table 5.2, the
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interaction effects of APOE4 status and pain percept level in both models were not statistically significant (p > .05), yet as is apparent, the strongest effects of APOE4 status were
observed at the weak and moderate pain levels (Cohen’s d = 0.50 to 0.59). A follow-up
analysis examining the effects of APOE4 on pain unpleasantness adjusting for differences
in stimulus intensity at each percept level across genetic groups indicated that the pattern
of results was little changed, with the APOE4 main effect becoming marginally significant
(p < .09) but the overall effect size increasing slightly (from d = 0.26 to d = 0.33).

Discussion
In this study, we found that cognitively healthy APOE4 positive individuals who are at
increased genetic risk of late-onset AD exhibit significantly reduced sensitivity to evoked
thermal pain relative to APOE4 negative individuals. However, when specific pain percepts are reached, APOE4 positive individuals report this pain to be more unpleasant than
individuals without an APOE4 allele. To the best of our knowledge, this is the first report
of an association of APOE4 allele status with an altered response to pain in a cognitively
healthy sample of adults across the life span. Notably, the observed psychophysical results in this work mirror a recent study in which the authors used a very similar study
design to test pain perception differences between cognitively healthy adults and people
with diagnosed AD age 65 and older (T. B. Monroe, Gibson, et al., 2016). As in the current
work, people with AD required a higher stimulus temperature than cognitively healthy
controls to report the perceptions of “warmth” “mild pain” and “moderate pain”. However, APOE status was not available for analysis in that prior work. In context of this
prioir work, these present results suggest that thermal evoked pain testing could serve as
a potential phenotypic biomarker of individuals at increased risk for AD. At minimum,
further research on this issue appears to be warranted in a larger sample. Differences observed between APOE4 positive and APOE4 negative cognitively normal individuals in
thermal percept detection levels and in pain unpleaseantness at each percept may hint at
possible mechanisms for how prodromal AD pathology may disrupt pain processing (T. B.
Monroe, Beach, et al., 2017; T. B. Monroe, Fillingim, et al., 2018; T. B. Monroe, Gibson, et al.,
2016; R. R. Romano et al., 2019). This possibility is consistent with other work suggesting
that alterations in other sensory systems are potential phenotypic markers for subsequent
AD risk (3. Romano R. R., Carter, and T. B. Monroe, 2020).
This study does have some limitations. First, the use of a perceptual matching
paradigm in which participants reported unpleasantness of pain at temperature intensities unique to each individual potentially leads to confounded assessmment for this outcome. In future work, this potential counfound can be overcome through using a series
of fixed temperatures across participants. Another limitation is the small sample size,
which reduced statistical power and likely adversely impacted ability to test the effect of
APOE4 at each percept level individually. Despite this limitation, the mixed effect models
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did demonstrate statistically significant overall differences as a function of APOE4 status
across the three percept levels. Moreover, the moderate effect sizes for between group
differences noted at the mild pain and moderate pain percept levels suggest that APOE4related differences in pain perception that are likely to be clinically meaningful. Future
studies should aim to replicate the current results in larger samples and with other types
of experimental pain stimuli, such as a mechanical pressure pain or ischemic pain.
As the prevalence of dementia is expected to triple over the next 30 years, more
evidence is needed to understand the altered pain experience in people with AD (“2020
Alzheimer’s disease facts and figures” 2020; Johannes et al., 2010). Carriers of the ε4 allele are at greater risk for amloyid deposition, impacting brain structures such as the hypothalamus and the prefrontal cortex, which may disrupt neural circuits mediating pain
perception and behavioral expression that result in differences in psychophysical measurements of pain (Cole et al., 2006; Scherder, Sergeant, and Swaab, 2003; Stubbs et al.,
2016).The results of this research demonstrate for the first time that alterations in evoked
pain responsiveness may be a potential phenotypic marker for identifying those at risk for
APOE4-related late-onset AD (3. Romano R. R., Carter, and T. B. Monroe, 2020). In the
clinical context, the possibility that APOE4 allele status may alter the risk of pain-related
suffering (either by directly increasing pain unpleasantness or delaying necessary medical care due to decreased pain sensitivity) irrespective of AD status may warrant further
exploration.
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Chapter 6
Discussion

Summary
The aim of this research was to find ways for primary care providers to recognize AD
early enough in the preclinical stage to affect outcomes of care. Chapter 2 presented the
first published manuscript, an integrative review, highlighting the complexity of barriers
that exist at each level of the health care system that contribute to limit diagnoses of AD by
PCPs. One study reviewed suggested that the comorbitities or complexity of the patients’
presenting problems makes it difficult to diagnose AD. Pain is a common cormorbidity
seen in AD and a main reason people interact with the health care system. This funding
led to the second published study. The second study was undertaken to explore how pain
may differ in those at risk for AD. Chapter 3 presented the results of a study demonstrating
that the experience of pain differs between males and females as a measure of cognition
worsens suggesting pain may be a useful marker of AD. This led to the third published
study. Chapter 4 presented a narrative review of the literature demonstrating that differences in senses have been associated with the different diagnostic categories and that
there is a paucity of research in how pain may be used as a marker of AD. This conclusion
formed the basis of the fourth study. Chapter 5 reported an analysis of data in a study
that included APOE4 association with pain response in cognitively healthy individuals.
This compared individuals at increased risk of AD experience pain based on their APOE4
status at a greater temperature and found that pain was more unpleasant when compared
to those without the increased risk of AD. We believe that this is the first time this finding has been reported. Further work is warranted to understand how the experience of
pain maybe used as a biomarker tool to identify those who are susceptible to subsequent
development of AD.

Limitations
A major limitation for the study that tested associations of APOE4 status and pain was the
small sample size. Future work should focus on enrolling more participants with a greater
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proportion of APOE4 positive individuals and exposing them to different types of experimental pain over a period of time. The results would also be stronger if a younger cohort
was followed and additional biomarkers were collected (e.g., MRI, CSF tau) to explore if
differences in the experience of pain is also different between those positive or negative
for markers of T or (N). Exploratory genetic markers could be collected, such as polymorphisms of the gene for cyclin-dependent kinase 5 (CDK5) which has been associated with
neuropathic pain and APOE. Further the differences in the specific genetic profiles can be
teased out with more subjects but may be too difficult to reach enrollment needs based on
the current distribution to clinical studies.

Recommendations for Future Directions
The search to identify preclinical markers of AD would provide clues to later onset of AD
in individuals at risk. This would allow for earlier interventions and the potential use of
disease modifying medications once approved. Older adults and their loved ones often
seek care from their primary care providers with initial concerns for memory. Their primary care providers have been identified as key to improve diagnosis which is important
because as we currently stand interventions aimed at PCPS to improve diagnosis are not
having the desired effect. There is evidence that primary care providers’ diagnostic accuracy is poor and it takes about 17 years for research to catch up to in clinical practice
(“2020 Alzheimer’s disease facts and figures” 2020). We need to identify earlier markers
of Alzheimer’s disease. The evidence of this research suggests pain as a possible early
marker of AD.
The evidence presented in this dissertation complements previous findings suggesting people at risk for AD based on carrying the ε4 allele had significantly great brain
activation in multiple regions involved in pain processing when compared to those without the ε4 allele (T. B. Monroe, Gore, Chen, et al., 2012). Those who were diagnosed with
AD needed greater temperatures to elicit pain when compared to cognitively normal participants. Even if pain proves to be a useful early marker, the difference found in this dissertation suggests further research is warranted into how AD pathology disrupts the pain
experience. Chronic pain is one of the leading comorbidities with AD and difficult to treat
in patients with AD. Others have shown AD patients get/receive fewer pain medicines
compared to healthy controls (T. B. Monroe, Carter, et al., 2013). The fact that there are
limited options available for chronic pain management in older adults with AD provides
direction from this dissertation that may lead to novel drug therapies.
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